Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.009
Buy
RSI(14)
50.424
Neutral
STOCH(KDJ)(9,3,3)
56.177
Sell
ATR(14)
0.462
High Vlolatility
CCI(14)
32.561
Neutral
Williams %R
52.740
Neutral
TRIX(12,20)
0.292
Sell
StochRSI(14)
0.000
Sell
Search
Kura Oncology Inc
KURAAdd to Watchlist
9.220USD
-0.520-5.34%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
818.50MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Kura Oncology Inc
Currency: USD Updated: 2026-05-15Key Insights
Kura Oncology Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 35 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.17.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kura Oncology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Kura Oncology Inc Highlights
StrengthsRisks
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
Growing
The company is in a growing phase, with the latest annual income totaling USD 67.48M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 67.48M.
Overvalued
The company’s latest PE is -2.75, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 91.73M shares, decreasing 22.20% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 8.40K shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
31.167
Target Price
+219.99%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Kura Oncology Inc is 6.82, ranking 180 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 18.27M, representing a year-over-year increase of 29.47%, while its net profit experienced a year-over-year increase of 27.69%.
Score
Financials
5.30
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
5.43
Operational Efficiency
10.00
Growth Potential
6.14
Shareholder Returns
7.23
Kura Oncology Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Kura Oncology Inc is 7.50, ranking 106 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.75, which is -11.66% below the recent high of -2.43 and -310.05% above the recent low of -11.29.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 35/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Kura Oncology Inc is 8.25, ranking 143 out of 382 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 76.00 and a low of 16.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
31.167
Target Price
+219.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Kura Oncology Inc
KURA
16
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Kura Oncology Inc is 7.14, ranking 97 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.99 and the support level at 8.49, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
9.526
Sell
MA10
9.447
Sell
MA20
9.301
Sell
MA50
8.915
Buy
MA100
8.910
Buy
MA200
9.067
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Kura Oncology Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 103.35%, representing a quarter-over-quarter increase of 4.16%. The largest institutional shareholder is James Simons, holding a total of 1.83M shares, representing 2.06% of shares outstanding, with 235.22% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kura Oncology Inc is 4.84, ranking 63 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.32
VaR
+5.12%
240-Day Maximum Drawdown
+39.04%
240-Day Volatility
+63.38%
Return
Best Daily Return
60 days
+8.28%
120 days
+14.53%
5 years
+46.13%
Worst Daily Return
60 days
-7.42%
120 days
-8.33%
5 years
-36.77%
Sharpe Ratio
60 days
+0.97
120 days
-0.52
5 years
+0.08
Risk Assessment
Maximum Drawdown
240 days
+39.04%
3 years
+76.46%
5 years
+76.46%
Return-to-Drawdown Ratio
240 days
+1.19
3 years
-0.06
5 years
-0.12
Skewness
240 days
+0.72
3 years
+1.26
5 years
+0.82
Volatility
Realised Volatility
240 days
+63.38%
5 years
+66.64%
Standardised True Range
240 days
+5.28%
5 years
+7.80%
Downside Risk-Adjusted Return
120 days
-87.61%
240 days
-87.61%
Maximum Daily Upside Volatility
60 days
+40.00%
Maximum Daily Downside Volatility
60 days
+40.61%
Liquidity
Average Turnover Rate
60 days
+1.66%
120 days
+1.70%
5 years
--
Turnover Deviation
20 days
-7.72%
60 days
-3.28%
120 days
-0.75%
Peer Comparison
Biotechnology & Medical Research
Kura Oncology Inc
KURA
7.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
